Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

Subscribe Listen in podnod RSS feed Show website

412 episodes
Updated Friday

Episodes412

Newest first

February 19 · 1 min
Pharmaceutical Executive Daily: FDA Plans to Remove Two Study Requirement for New Drug Approvals
In today’s Pharmaceutical Executive Daily, the FDA reportedly removes its two-study requirement for new drug approvals, Hims & Hers enters a $1 billion agreement to acquire Eucalyptus, and experts examine how FDA can help ease early-stage clinical trial bottlenecks.
February 18 · 1 min
Pharmaceutical Executive Daily: FDA Initiates Review of Moderna’s Seasonal Influenza Vaccine
In today’s Pharmaceutical Executive Daily, the FDA begins reviewing Moderna’s seasonal flu vaccine under a revised regulatory approach, Eli Lilly signs a $100 million licensing agreement with CSL for an anti- IL-6 monoclonal antibody., and Southern Florida emerges as a growing biotech hub.
February 17 · 1 min
Pharmaceutical Executive Daily: FDA Approves New Dosing Schedule for Rybrevant Faspro
In today’s Pharmaceutical Executive Daily, the FDA approves a monthly dosing schedule for Rybrevant Faspro, HHS Secretary Robert F. Kennedy Jr. revises the agency’s leadership team, and industry expert Sandy Tammisetty discusses what it takes to deliver actual value in today’s pharmaceutical landscape.
February 16 · 1 min
Pharmaceutical Executive Daily: Disc Medicine Receives CRL from FDA for Bitopertin
In today’s Pharmaceutical Executive Daily, the FDA issues a Complete Response Letter for Disc Medicine’s bitopertin in EPP, Edwards Lifesciences lifts its anti-copycat policy, and industry leaders examine how to scale global medical digital transformation while ensuring local fit.
February 13 · 1 min
Pharmaceutical Executive Daily: Eli Lilly's $1.5 Billion Stockpile of Orforglipron
In today’s Pharmaceutical Executive Daily, Eli Lilly builds a $1.5 billion stockpile of Orforglipron ahead of an FDA decision, PTC Therapeutics withdraws and plans to resubmit its Translarna NDA, and a former AstraZeneca executive is charged with multiple offenses in China.
February 11 · 1 min
Pharmaceutical Executive Daily: FDA Issues Refusal-to-File Letter to Moderna
In today’s Pharmaceutical Executive Daily, the FDA issues a refusal-to-file letter to Moderna for its seasonal influenza vaccine as the company secures a long-term agreement in Mexico, industry leaders assess China’s evolving role in global pharma strategy, and the FDA makes a decision on Keytruda in platinum-resistant ovarian cancer.
February 10 · 1 min
Pharmaceutical Executive Daily: Specialized Wealth Management for BioPharmaceutical Sales
In today’s Pharmaceutical Executive Daily, frontline biopharma sales professionals are increasingly turning to specialized wealth management advisory services, QuantX Biosciences and Pandorum Technologies close Series B financing rounds, and Iambi enters a $1 billion collaboration with Takeda to advance small-molecule programs.
February 10 · 17 min
Bets and Balances: Riding the Risk-and-Innovation Pendulum in Biotech
In a podcast conversation with Pharm Exec, Ken Banta, founder and CEO of The Vanguard Network, and Andrew Hall, CEO of Consano Bio, discuss what effective leadership looks like in today’s volatile capital and regulatory climates for emerging biotechs. Part 1 of the conversation explores why Banta and Hall believe CEOs of these companies must act as stabilizers and translators—balancing risk with opportunity and turning complex scientific innovation into clear strategy for investors, regulators, and employees alike. Highlights of the discussion include: The EQ imperative: leading through persuasion and influence, not dictates. “It’s not about the science; it’s about the people.” The best CEOs follow a four-core formula Early stage’s mindset mix (end-game vs journey)—and the rewards of “failing fast” Why Series A’s are the “lifeblood of biotech”
February 9 · 1 min
Pharmaceutical Executive Daily: Hims & Hers Removes Access to New Compounded Semaglutide Pill
In today’s Pharmaceutical Executive Daily, Hims & Hers withdraws access to its compounded semaglutide pill following a controversy filled launch, next-generation trial designs increasingly integrate real-world data, and Eli Lilly enters an $8 billion strategic collaboration involving Innovent and Orna Therapeutics.
February 6 · 1 min
Pharmaceutical Executive Daily: The Launch of TrumpRx
In today’s Pharmaceutical Executive Daily, TrumpRx officially launches, the FDA moves against mass marketing of illegal copycat drugs, and AI emerges as a force multiplier for small and mid-size biotech companies
February 5 · 1 min
Pharmaceutical Executive Daily: FDA Approves First and Only Oral Film Treatment for Erectile Dysfunction
In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical protocols should be treated as product launch blueprints, and Veradermics completes an upsized $256 million IPO.
February 4 · 1 min
Pharmaceutical Executive Daily: Susan G. Komen Releases Breast Cancer Outlook for 2026
In today’s Pharmaceutical Executive Daily, Susan G. Komen releases its 2026 breast cancer progress outlook, industry leaders explore how pharma can tap into emerging talent hubs, and Novartis’ Q4 results highlight mounting pressure from its upcoming patent cliff.
February 3 · 1 min
Pharmaceutical Executive Daily: SanegeneBio's $1.5 Billion License Agreement with Genentech
In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application for a subcutaneous indication of Saphnelo, and SanegeneBio enters a $1 billion global licensing agreement with Genentech focused on RNAi development.
February 2 · 1 min
Pharmaceutical Executive Daily: FDA Reveals PreCheck Pilot Program
In today’s Pharmaceutical Executive Daily, the FDA introduces a PreCheck pilot program aimed at strengthening domestic manufacturing oversight, an ACIP member alleges FDA leadership halted a decision related to COVID-19 vaccines, and Eli Lilly announces plans for a $3 billion manufacturing facility in Pennsylvania.
January 30 · 1 min
Pharmaceutical Executive Daily: Public Citizen Sues The Trump Administration Over Undisclosed Drug Price Agreements
In today’s Pharmaceutical Executive Daily, Public Citizen files suit over undisclosed drug pricing agreements involving Pfizer and Eli Lilly, HHS releases new guidance aimed at lowering prescription drug costs through direct-to-consumer programs, and AstraZeneca enters a multibillion-dollar collaboration with CSPC Pharmaceutical Group.
January 29 · 1 min
Pharmaceutical Executive Daily: The Disconnect Between Pharma and MedTech
In today’s Pharmaceutical Executive Daily, MJH Life Sciences CEO, Mike Hennessy Jr. examines why pharma and medtech still struggle to deliver truly integrated healthcare solutions, questions emerge around U.S. funding tied to global vaccine policy shifts, and the FDA approves a new treatment option for adults with presbyopia.
January 28 · 1 min
Pharmaceutical Executive Daily: Eli Lilly Enters $1 Billion Research Collaboration with Seamless Therapeutics
In today’s Pharmaceutical Executive Daily, Insilico Medicine and Qilu Pharmaceuticals launch a $120 million collaboration to advance AI-driven cardiometabolic therapies, Eli Lilly enters a billion-dollar research partnership targeting hearing loss, and industry leaders examine what it takes to bring breakthrough rare disease products to patients.
January 27 · 1 min
Pharmaceutical Executive Daily: Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist
In today’s pharmaceutical executive daily, Roche reports positive Phase II results for a dual GLP-1/GIP receptor agonist, procurement leaders reassess compliance risks tied to unmanaged tail spend, and Boehringer Ingelheim enters a $1 billion collaboration with Simcere to advance bispecific antibody research.
January 26 · 1 min
Pharmaceutical Executive Daily: Mirum Pharmaceuticals Acquires Bluejay Therapeutics
In todays pharmaceutical executive daily, Mirum Pharmaceuticals strengthens its rare disease portfolio through a $268 million acquisition, industry experts examine why data visualization remains a weak point in biotech decision-making, and pediatricians weigh in on evolving vaccine guidance amid ongoing debate.
January 23 · 1 min
Pharmaceutical Executive Daily: Tariff Uncertainty Accelerates Manufacturing Shifts
In today’s Pharmaceutical Executive Daily, tariff uncertainty triggers a short-term surge in pharmaceutical manufacturing activity, workforce burnout threatens the stability of the blood supply, and industry leaders assess whether artificial intelligence in pharma is reaching a critical inflection point.